drugset / Trial / NCT00036088

Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia

NCT00036088

Phase 4 Completed 530 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine how Olanzapine compares to an active comparator in the treatment of schizophrenia

Timeline

Start
2001-08
Primary completion
Completion
2002-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Olanzapine Small molecule

Indications